Related references
Note: Only part of the references are listed.Novel Class of Benzoic Acid Ester Derivatives as Potent PDE4 Inhibitors for Inhaled Administration in the Treatment of Respiratory Diseases
Elisabetta Armani et al.
JOURNAL OF MEDICINAL CHEMISTRY (2014)
Phosphodiesterase inhibitors. Part 5: Hybrid PDE3/4 inhibitors as dual bronchorelaxant/anti-inflammatory agents for inhaled administration
Koji Ochiai et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2013)
Transcriptome sequencing (RNA-Seq) of human endobronchial biopsies: asthma versus controls
Ching Yong Yick et al.
EUROPEAN RESPIRATORY JOURNAL (2013)
The Selective Phosphodiesterase 4 Inhibitor Roflumilast and Phosphodiesterase 3/4 Inhibitor Pumafentrine Reduce Clinical Score and TNF Expression in Experimental Colitis in Mice
Florian Rieder et al.
PLOS ONE (2013)
Roflumilast Inhibits Respiratory Syncytial Virus Infection in Human Differentiated Bronchial Epithelial Cells
Manuel Mata et al.
PLOS ONE (2013)
Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis
Barbara P. Yawn et al.
INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (2013)
Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials
Lui G. Franciosi et al.
LANCET RESPIRATORY MEDICINE (2013)
Effect of the Mixed Phosphodiesterase 3/4 Inhibitor RPL554 on Human Isolated Bronchial Smooth Muscle Tone
Luigino Calzetta et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2013)
Oxidative stress-induced glucocorticoid resistance is prevented by dual PDE3/PDE4 inhibition in human alveolar macrophages
J. Milara et al.
CLINICAL AND EXPERIMENTAL ALLERGY (2011)
Critical Modifier Role of Membrane-Cystic Fibrosis Transmembrane Conductance Regulator-Dependent Ceramide Signaling in Lung Injury and Emphysema
Manish Bodas et al.
JOURNAL OF IMMUNOLOGY (2011)
In Vivo Characterization of GSK256066, a High-Affinity Inhaled Phosphodiesterase 4 Inhibitor
Anthony T. Nials et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
PDE4 inhibition drives resolution of neutrophilic inflammation by inducing apoptosis in a PKA-PI3K/Akt-dependent and NF-κB-independent manner
Lirlandia P. Sousa et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2010)
Roflumilast for the treatment of chronic obstructive pulmonary disease
Klaus F Rabe
Expert Review of Respiratory Medicine (2010)
The inhaled phosphodiesterase 4 inhibitor GSK256066 reduces allergen challenge responses in asthma
Dave Singh et al.
RESPIRATORY RESEARCH (2010)
A controlled trial of 6-weeks' treatment with a novel inhaled phosphodiesterase type-4 inhibitor in COPD
J. Vestbo et al.
EUROPEAN RESPIRATORY JOURNAL (2009)
Roflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trials
Peter M. A. Calverley et al.
LANCET (2009)
Phosphodiesterase 4 inhibitor GPD-1116 markedly attenuates the development of cigarette smoke-induced emphysema in senescence-accelerated mice P1 strain
Hiroaki Mori et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2008)
Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease - Results from the TORCH study
Bartolome R. Celli et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
A major functional role for phosphodiesterase 4D5 in human airway smooth muscle cells
Charlotte K. Billington et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2008)
Short-term or long-term treatments with a phosphodiesterase-4 (PDE4) inhibitor result in opposing agonist-induced Ca2+ responses in endothelial cells
M. Campos-Toimil et al.
BRITISH JOURNAL OF PHARMACOLOGY (2008)
Partial reversal of experimental pulmonary hypertension by phosphodiesterase-3/4 inhibition
E. Dony et al.
EUROPEAN RESPIRATORY JOURNAL (2008)
Nicotine and oxidative cigarette smoke constituents induce immune-modulatory and pro-inflammatory dendritic cell responses
Robert Vassallo et al.
MOLECULAR IMMUNOLOGY (2008)
Reduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPD
Diana C. Grootendorst et al.
THORAX (2007)
Investigation of the molecular mechanisms preceding PDE4 inhibitor-induced vasculopathy in rats:: Tissue inhibitor of metalloproteinase 1, a potential predictive biomarker
Nicolas Dagues et al.
TOXICOLOGICAL SCIENCES (2007)
Inhibition of TGF-β induced lung fibroblast to myofibroblast conversion by phosphodiesterase inhibiting drugs and activators of soluble guanylyl cyclase
Torsten R. Dunkern et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2007)
Both protein kinase a and exchange protein activated by cAMP coordinate adhesion of human vascular endothelial cells
Stuart J. Netherton et al.
CIRCULATION RESEARCH (2007)
Survival after lung volume reduction in chronic obstructive pulmonary disease - Insights from small airway pathology
James C. Hogg et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
PI3Kγ is required for PDE4, not PDE3, activity in subcellular Microdomains containing the sarcoplasmic reticular calcium ATPase in cardiomyocytes
Benoit-Gilles Kerfant et al.
CIRCULATION RESEARCH (2007)
Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease
Peter M. A. Calverley et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2007)
Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells:: Predominant role of PDE4D
Daniel Peter et al.
JOURNAL OF IMMUNOLOGY (2007)
SAR of a series of 5,6-dihydro-(9H)-pyrazolo[3,4-c]-1,2,4-triazolo[4,3-α]pyridines as potent inhibitors of human eosinophil phosphodiesterase
Allen J. Duplantier et al.
JOURNAL OF MEDICINAL CHEMISTRY (2007)
COPD exacerbations: defining their cause and prevention
Jadwiga A. Wedzicha et al.
LANCET (2007)
Alterations in regulation of energy homeostasis in cyclic nucleotide phosphodiesterase 3B-null mice
Young Hun Choi et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Profiling human phosphodiesterase genes and splice isoforms
Jonathan Bingham et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
The pharmacology of two novel long-acting phosphodiesterase 3/4 inhibitors, RPL554 [9,10-dimethoxy-2(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one] and RPL565 [6,7-dihydro-2-(2,6-diisopropylphenoxy)-9,10-dimethoxy-4H-pyrimido[6,1-a]isoquinolin-4-one]
Victoria Boswell-Smith et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Hypoxia-induced remodelling of PDE4 isoform expression and cAMP handling in human pulmonary artery smooth muscle cells
Jennifer Millen et al.
EUROPEAN JOURNAL OF CELL BIOLOGY (2006)
Involvement of MMP-12 and phosphodiesterase type 4 in cigarette smoke-induced inflammation in mice
O. Leclerc et al.
EUROPEAN RESPIRATORY JOURNAL (2006)
A phosphodiesterase 4 inhibitor inhibits matrix protein deposition in airways in vitro
Janette K. Burgess et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)
Characterization of the inflammatory response to a highly selective PDE4 inhibitor in the rat and the identification of biomarkers that correlate with toxicity
GN Dietsch et al.
TOXICOLOGIC PATHOLOGY (2006)
Phosphodiesterase-4 as a potential drug target
KYJ Zhang et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2005)
Inhaled tolafentrine reverses pulmonary vascular remodeling via inhibition of smooth muscle cell migration
S Pullamsetti et al.
RESPIRATORY RESEARCH (2005)
Phosphodiesterase 4D deficiency in the ryanodine-receptor complex promotes heart failure and arrhythmias
SE Lehnart et al.
CELL (2005)
Roflumilast fully prevents emphysema in mice chronically exposed to cigarette smoke
PA Martorana et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2005)
Dynamic activation of cystic fibrosis transmembrane conductance regulator by type 3 and type 4D phosphodiesterase inhibitors
SS Liu et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2005)
Oxidative stress and airway inflammation in severe exacerbations of COPD
EM Drost et al.
THORAX (2005)
Selective PDE4 inhibitors as potent anti-inflammatory drugs for the treatment of airway diseases
V Lagente et al.
MEMORIAS DO INSTITUTO OSWALDO CRUZ (2005)
The effect of selective phosphodiesterase isoenzyme inhibition on neutrophil function in vitro
NA Jones et al.
PULMONARY PHARMACOLOGY & THERAPEUTICS (2005)
Vascular endothelial cell cyclic nucleotide phosphodiesterases and regulated cell migration: Implications in angiogenesis
SJ Netherton et al.
MOLECULAR PHARMACOLOGY (2005)
Antiremodeling effects of iloprost and the dual-selective phosphodiesterase 3/4 inhibitor tolafentrine in chronic experimental pulmonary hypertension
RT Schermuly et al.
CIRCULATION RESEARCH (2004)
Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers
R Barber et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2004)
Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation
M Ariga et al.
JOURNAL OF IMMUNOLOGY (2004)
Preferential inhibition of T helper 1, but not T helper 2, cytokines in vitro by L-826,141 [4-{2-(3,4-bis-difluromethoxyphenyl)-2-{4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-phenyl]-ethyl}-3-methylpyridine-1-oxide], a potent and selective phosphodiesterase 4 inhibitor
D Claveau et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2004)
Differential type 4 cAMP-specific phosphodiesterase (PDE4) expression and functional sensitivity to PDE4 inhibitors among rats, monkeys and humans
H Bian et al.
BIOCHEMICAL PHARMACOLOGY (2004)
Modulation of matrix metalloproteinase production from human lung fibroblasts by type 4 phosphodiesterase inhibitors
CAE Martin-Chouly et al.
LIFE SCIENCES (2004)
Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors
SD Edmondson et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2003)
Biopsy neutrophilia, neutrophil chemokine and receptor gene expression in severe exacerbations of chronic obstructive pulmonary disease
YS Qiu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2003)
PDE4D plays a critical role in the control of airway smooth muscle contraction
C Méhats et al.
FASEB JOURNAL (2003)
In vivo efficacy in airway disease models of N-(3,5-dichloropyrid-4-yl)-[1-(4-fluorobenzyl)-5-hydroxy-indole-3-yl]-glyoxylic acid amide (AWD 12-281), a selective phosphodiesterase 4 inhibitor for inhaled administration
H Kuss et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Adenosine receptors and phosphodiesterase inhibitors stimulate Cl- secretion in Calu-3 cells
BR Cobb et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2003)
Phosphodiesterase 4 inhibitors reduce human dendritic cell inflammatory cytokine production and Th1-polarizing capacity
HC Heystek et al.
INTERNATIONAL IMMUNOLOGY (2003)
Type 4A cAMP-specific phosphodiesterase is stored in granules of human neutrophils and eosinophils
KB Pryzwansky et al.
CELL AND TISSUE RESEARCH (2003)
Synthesis and structure-activity relationships of cis-tetrahydrophthalazinone/pyridazinone hybrids:: A novel series of potent dual PDE3/PDE4 inhibitory agents
M Van der Mey et al.
JOURNAL OF MEDICINAL CHEMISTRY (2003)
Bronchodilator effects of intravenous olprinone, a phosphodiesterase 3 inhibitor, with and without aminophylline in asthmatic patients
S Myou et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling
M Conti et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Inhibitors of cyclic nucleotide phosphodiesterase PDE3 as adjunct therapy for dilated cardiomyopathy
MA Movsesian et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2002)
Amplification of the pulmonary vasodilatory response to inhaled iloprost by subthreshold phosphodiesterase types 3 and 4 inhibition in severe pulmonary hypertension
HA Ghofrani et al.
CRITICAL CARE MEDICINE (2002)
Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in them treatment of chronic obstructive pulmonary disease
DA Mahler et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2002)
Cyclic AMP-dependent transcriptional up-regulation of phosphodiesterase 4D5 in human airway smooth muscle cells -: Identification and characterization of a novel PDE4D5 promoter
IR Le Jeune et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Cyclic nucleotide research - still expanding after half a century
JA Beavo et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2002)
PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels
T Kohyama et al.
AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY (2002)
Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-α responses
SLC Jin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Immunopharmacological potential of selective phosphodiesterase inhibition.: I.: Differential regulation of lipopolysaccharide-mediated proinflammatory cytokine (interleukin-6 and tumor necrosis factor-α) biosynthesis in alveolar epithelial cells
JJ Haddad et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2002)
Identification and quantification of phosphodiesterase 4 subtypes in CD4 and CD8 lymphocytes from healthy and asthmatic subjects
LJ Landells et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C4-induced contractions in passively sensitized human airways
DT Schmidt et al.
BRITISH JOURNAL OF PHARMACOLOGY (2000)
Potent effects of novel anti-platelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity
T Sudo et al.
BIOCHEMICAL PHARMACOLOGY (2000)
Share Paper
